Jared Holz, Mizuho, joins 'Fast Money' to recap Novo Nordisk's bid for Metsera and ELi Lilly soaring after earnings beat.

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Shares of Danish rival Novo Nordisk slipped after it sought to snatch Pfizer target Metsera from the American drug giant's arms. Novo launched an unsolicited bid valued at up to $9 billion for obesity ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly.

Novo Nordisk faces headwinds from regulatory uncertainty, competitive efficacy gaps with Eli Lilly and technical downward ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

Novo Nordisk, a leader in weight-loss drugs, is offering $6 billion up front with the potential for later milestone payments ...

Metsera has become the obesity drug market's hottest ticket. The New York-based biotech is at the centre of a bidding war ...

Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, announced Thursday an unsolicited bid to acquire obesity treatment maker Metsera, topping an offer from US ...

US President Trump wraps up his Asia tour with major trade and security announcements, while Israel’s Netanyahu issues a ...